

Oxygen therapy for acutely ill medical patients: a clinical practice guideline

Reed A C Siemieniuk,¹ Derek K Chu,² Lisa Ha-Yeon Kim,² Maria-Rosa Güell-Rous,³ Waleed Alhazzani,¹² Paola M Soccia,⁴⁵ Paul J Karanicolas,⁶ Pauline D Farhoumand,⁷ Jillian L K Siemieniuk,⁸ Imran Satia,² Elvis M Irusen,⁹ Marwan M. Refaat,¹⁰ J. Stephen Mikita,¹¹ Maureen Smith,¹² Dian N Cohen,¹³ Per O Vandvik,¹⁴ Thomas Agoritsas,¹⁷¹⁵ Lyubov Lytvyn,¹ Gordon H Guyatt¹²

Full author details can be found at the end of the article

Correspondence to:

R A C Siemieniuk
reed.siemieniuk@medportal.ca

Cite this as: *BMJ* 2018;363:k4169
doi: 10.1136/bmj.k4169

This *BMJ* Rapid Recommendation article is one of a series that provides clinicians with trustworthy recommendations for potentially practice changing evidence. *BMJ* Rapid Recommendations represent a collaborative effort between the MAGIC group (<http://magicproject.org/>) and *The BMJ*. A summary is offered here and the full version including decision aids is on the MAGICapp (<https://app.magicapp.org/>), for all devices in multilayered formats. Those reading and using these recommendations should consider individual patient circumstances, and their values and preferences and may want to use consultation decision aids in MAGICapp to facilitate shared decision making with patients. We encourage adaptation and contextualisation of our recommendations to local or other contexts. Those considering use or adaptation of content may go to MAGICapp to link or extract its content or contact *The BMJ* for permission to reuse content in this article. Series adviser Rafael Perera-Salazar.

What is the best way to use oxygen therapy for patients with an acute medical illness? A systematic review published in the *Lancet* in April 2018 found that supplemental oxygen in inpatients with normal oxygen saturation increases mortality.¹ Its authors concluded that oxygen should be administered conservatively, but they did not make specific recommendations on how to do it. An international expert panel used that review to inform this guideline. It aims to promptly and transparently translate potentially practice-changing evidence to usable recommendations for clinicians and patients.² The panel used the GRADE framework and following standards for trustworthy guidelines.³

The panel asked;

- In acutely ill patients, when should oxygen therapy be started? (What is the lower limit of peripheral capillary oxygen saturation (SpO₂)?)
- In acutely ill patients receiving oxygen therapy, how much oxygen should be given? (What is the upper limit of SpO₂?)

The panel makes a strong recommendation for maintaining an oxygen saturation of no more than 96% in acutely ill medical patients (upper limit). The panel did not make a recommendation on when to

start (the lower limit) for all medical patients because there was not enough evidence. Instead, the panel suggests that patients with acute stroke or myocardial infarction and a SpO₂ ≥90% not receive supplemental oxygen (a weak recommendation if SpO₂ is 90-92% and a strong recommendation if 93-100%). Box 1 shows the article and evidence linked to this Rapid Recommendation. The infographic provides an overview of the key absolute benefits and harms, as well as the quality of evidence that informed each of the recommendations.

The panel was confident that the recommendation against letting oxygen saturation rise above 96% applies to almost all patients in hospital with a medical problem. The recommendation also applies to pre-hospital care. The evidence may apply to surgical and obstetric patients, but the panel did not review the evidence on postoperative healing and infections and therefore decided not to comment on these patients. Similarly, the panel did not review the evidence on oxygen therapy in neonates and infants.

Current practice


Supplemental oxygen therapy is widely used in hospitals: 25% or more of patients who visit the emergency department receive oxygen.⁴ Clinicians often give oxygen to many patients presenting with stroke without hypoxaemia, and to almost all patients presenting with myocardial infarction.⁵ Until recently, many healthcare professionals believed that oxygen had little or no harm

WHAT YOU NEED TO KNOW

- It is a longstanding cultural norm to provide supplemental oxygen to sick patients regardless of their blood oxygen saturation
- A recent systematic review and meta-analysis has shown that too much supplemental oxygen increases mortality for medical patients in hospital
- For patients receiving oxygen therapy, aim for peripheral capillary oxygen saturation (SpO₂) of ≤96% (strong recommendation)
- For patients with acute myocardial infarction or stroke, do not initiate oxygen therapy in patients with SpO₂ ≥90% (for ≥93% strong recommendation, for 90-92% weak recommendation)
- A target SpO₂ range of 90-94% seems reasonable for most patients and 88-92% for patients at risk of hypercapnic respiratory failure; use the minimum amount of oxygen necessary


Box 1 | Linked resources in this *BMJ* Rapid Recommendations cluster

- Siemieniuk RAC, Chu DK, Kim LH-Y, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. *BMJ* 2018;363:k4169
 - Summary of the results from the Rapid Recommendation process
- Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. *Lancet* 2018;391:1693-705.
 - Review and meta-analysis of all available randomised trials that assessed oxygen therapy for acute illnesses
- MAGICapp (<https://app.magicapp.org/public/guideline/jxQ70L>)
 - Expanded version of the results with multilayered recommendations, evidence summaries, and decision aids for use on all devices



Recommendation 1 - upper limit

Applies to:



Including:

✔ Critically ill surgical patients

Does not apply to patients with:

✘ Carbon monoxide poisoning

✘ Cluster headaches

✘ Sickle cell crisis

✘ Pneumothorax

≥97% target

An upper limit of oxygen saturation target 97% or higher



or

≤96% target

An upper limit of oxygen saturation target of no more than 96%



≥97% target

≤96% target

Strong

Weak

Weak

Strong

We recommend that oxygen saturation be maintained no higher than 96%

Comparison of benefits and harms



Key practical issues

Oxygen therapy

When upper limits for oxygen saturation are lowered, nursing demands will increase

Sometimes causes one or more of: claustrophobia, nasal or throat dryness, hoarseness, irritation

Oxygen delivery devices may hinder patients' freedom of movement, eating, drinking, and communication

No oxygen therapy

No practical issues

Ideal levels

The ideal upper limit for those receiving oxygen therapy is probably lower than 96%, for example 94%

Values and preferences

Almost all patients will place a high value on avoiding even a small increased risk of death

© 2018 BMJ Publishing group Ltd.

Disclaimer: This infographic is not a clinical decision aid. This information is provided without any representations, conditions or warranties that it is accurate or up to date. BMJ and its licensors assume no responsibility for any aspect of treatment administered with the aid of this information. Any reliance placed on this information is strictly at the user's own risk. For the full disclaimer wording see BMJ's terms and conditions. <http://www.bmj.com/company/legal-information/>


thebmj

See an interactive version of this graphic online

<http://bit.ly/BMJrroxy>

Recommendation 2 - lower limit (90-92%)

Applies to people with:



Oxygen therapy

Provision of supplemental oxygen



or

No oxygen therapy

No provision of supplemental oxygen



Oxygen therapy

No oxygen therapy


Strong Weak Weak Strong

We suggest not providing oxygen therapy

Comparison of benefits and harms - patients with stroke



Comparison of benefits and harms - patients with myocardial infarction



Key practical issues

Oxygen therapy

- Sometimes causes one or more of: claustrophobia, nasal or throat dryness, hoarseness, irritation
- Oxygen delivery devices may hinder patients' freedom of movement, eating, drinking, and communication

No oxygen therapy

No practical issues

Ideal levels


The ideal oxygen saturation at which to start oxygen therapy is uncertain, but is probably 90% or lower

Values and preferences

Wearing a mask or nasal prongs can be uncomfortable. However, aside from terminally ill patients, almost all patients are likely to accept this discomfort for even a small reduction in chance of death

Recommendation 3 - lower limit (>92%)

Applies to people with:



Oxygen therapy

Provision of supplemental oxygen



or

No oxygen therapy

No provision of supplemental oxygen



Oxygen therapy

No oxygen therapy

Strong

Weak

Weak


Strong

We recommend not providing oxygen therapy

Comparison of benefits and harms - patients with stroke



Comparison of benefits and harms - patients with myocardial infarction



Key practical issues

Oxygen therapy

Sometimes causes one or more of: claustrophobia, nasal or throat dryness, hoarseness, irritation

Oxygen delivery devices may hinder patients' freedom of movement, eating, drinking, and communication

No oxygen therapy

No practical issues

Ideal levels

The ideal oxygen saturation at which to start oxygen therapy is uncertain, but is likely below 93%

Values and preferences

Wearing a mask or nasal prongs can be uncomfortable. However, aside from terminally ill patients, almost all patients are likely to accept this discomfort for even a small reduction in chance of death

Table 1 | Current guidance on supplemental oxygen therapy

Organisation	Condition	Recommendations	
		Lower limit	Upper limit
AARC, 2002 ⁹	All patients in acute care facility	Provide oxygen if SaO ₂ <90%	No upper limit
AHA/ASA, 2018 ⁹	Ischaemic stroke	Provide oxygen to maintain SaO ₂ >94%	No upper limit
EAN, 2018 ¹⁰	Ischaemic stroke	Provide oxygen to maintain normoxia in patients with SaO ₂ <95%. Routine use of O ₂ is not recommended	None mentioned
AHA, 2013 ¹¹	Myocardial infarction with ST elevation	Provide oxygen in patients with SaO ₂ <90%, heart failure, or dyspnoea	No upper limit
ESC, 2017 ¹²	Myocardial infarction with ST elevation	Provide oxygen in patients with hypoxaemia (SaO ₂ <90% or PaO ₂ <60 mm Hg). Routine oxygen not recommended if SaO ₂ ≥90%	No upper limit
ESC, 2015 ¹³	Myocardial infarction without ST elevation	Provide oxygen blood oxygen saturation <90% or respiratory distress.	No upper limit
BTS, 2017 ¹⁴	Acute medical conditions	Provide oxygen if SaO ₂ <94% for most acutely ill patients; <88% for patients with hypercapnia	98% for most patients, 92% for patients with hypercapnia
TSANZ ¹⁵	Acute medical conditions	Provide oxygen if SpO ₂ <92%	96% for most patients

AARC=American Association for Respiratory Care; AHA=American Heart Association; ASA=American Stroke Association; EAN=European Academy of Neurology; ESC=European Society of Cardiology; BTS=British Thoracic Society; TSANZ=Thoracic Society of Australia and New Zealand.
SaO₂=oxygen saturation; PaO₂=partial pressure of oxygen; SpO₂=peripheral capillary oxygen saturation

for acutely ill adults. In addition to mortality, other difficulties caused by oxygen can include nasal or throat irritation and hampered mobility. Doctors first used oxygen for medical purposes in the 19th century,⁶ and its use became routine in the early 20th century.⁷ Modern guidelines vary in their advice on when to give oxygen for acute medical conditions and how much to give (see table 1).

HOW THIS RECOMMENDATION WAS CREATED

Our international panel included methodologists, a respiratory therapist/technician, a nurse, patient partners who have been hospitalised for an acute medical condition, pulmonologists, intensivists, internists, an anaesthesiologist, a cardiologist, emergency physicians, and a surgeon (see appendix 1 on [bmj.com](http://www.bmj.com) for details of panel members). They decided on the scope of the recommendation and the outcomes most important to patients. The panel identified three key patient-important outcomes: mortality, hospital acquired infections, and length of hospitalisation. For two specific populations for which there was substantial randomised evidence available, the panel noted additional key outcomes: for patients with stroke, disability; and for patients with acute myocardial infarction, recurrent myocardial infarction, revascularisation, and chest pain.

The panel met to discuss the evidence and formulate a recommendation. No member had financial conflicts of interest; intellectual and professional conflicts were minimised and are transparently described (appendix 2 on [bmj.com](http://www.bmj.com)). The panel followed the *BMJ* Rapid Recommendations procedures for creating a trustworthy recommendation,² including using the GRADE approach to critically appraise the evidence and create recommendations (appendix 3 on [bmj.com](http://www.bmj.com)).³ The panel considered the benefits, as well as any harms and burdens, of oxygen therapy, the certainty (quality) of the evidence for each outcome, typical and expected variations in patient values and preferences, acceptability, and feasibility.²² Within the GRADE framework, recommendations can be either strong or weak (also known as conditional), and for or against a specific course of action.²³

The panel considered several key practical issues: psychological comfort from oxygen, discomfort (such as nasal irritation), and feasibility (such as impact on nursing resources). The panel was interested in knowing whether the impacts of oxygen were different in different medical conditions or study populations.

When to start oxygen—Peripheral capillary oxygen saturation (SpO₂) thresholds typically trigger the use of oxygen treatment. Thresholds range from SpO₂ <90% to <95% in guidelines. Recommendations for starting oxygen in specific groups vary: patients with stroke with SpO₂ <95%,⁹ and, regardless of SpO₂, those experiencing an acute myocardial infarction who feel breathless, are offered oxygen.¹¹

When to stop oxygen—Many guidelines do not say how much is too much. Healthcare workers may respond to this advice by keeping a buffer between a patient’s SpO₂ and the lower limit (for example, by keeping the SpO₂ close to 100%). Some guidelines advocate targeting a SpO₂ range. Proposed limits range from 98% for most patients, to an upper limit of 92% for patients with risk of hypercapnic respiratory failure, such as patients with chronic obstructive pulmonary disease.¹⁵

The evidence

A recent systematic review and meta-analysis of randomised controlled trials of acutely ill adults quantified whether inpatients were at greater risk of death with liberal or conservative oxygen therapy.¹ Patients randomised to liberal oxygen therapy were more likely to die (risk ratio 1.21 (95% confidence interval 1.03 to 1.43)). The increase in mortality was highest in the trials with the greatest increase in SpO₂; this suggests a dose-response relation and strengthens the inference that excessive oxygen is a cause of death. The review included 25 randomised controlled trials. Figure 2 outlines key study and participant characteristics. This shows that the results apply to a wide variety of patient groups.

Upper limit of oxygen therapy

The panel had moderate certainty that oxygen increases mortality when the SpO₂ is above 96%. Providing supplemental oxygen above a SpO₂ of 96% probably increases mortality by around 1%. There is probably no difference in length of hospitalisation or risk of hospital acquired infections. Average (median) SpO₂ was 96% in participants randomised to none or limited oxygen therapy. The evidence was rated down from high to moderate certainty for indirectness (uncertain applicability) because the trials used varying SpO₂ thresholds, leaving some uncertainty regarding the value above which mortality increases.




Fig 2 | Characteristics of patients and trials included in systematic review of the use of oxygen therapy in acutely ill adults

Lower limit of oxygen therapy

The evidence regarding the lower limit comes from the patients who were included in the clinical trials with baseline SpO₂ over 90%. The evidence in patients with initially higher SpO₂ (>92%) is more certain because most patients in the trials had a baseline SpO₂ above 92%. For example, in the largest of eight trials of patients with stroke only 240 patients (3.1% of 7677 participants) had an initial SpO₂ of 90-93.9%.¹⁶ For myocardial infarction, six trials enrolled 7898 patients: in the largest trial, 1062 patients (16.0%) had an initial SpO₂ ≤94%.¹⁷ For all outcomes, the panel rated down the quality of the evidence for indirectness (uncertain applicability) in patients with a SpO₂ of 90-92%. Because trials informing the lower limit of when to start oxygen were restricted to patients with stroke and myocardial infarction, whether the evidence applies to patients without these conditions is uncertain.

The confidence intervals around the absolute effects in both stroke and myocardial infarction demonstrate that administering supplemental oxygen in patients

with these conditions is unlikely to result in an important reduction in mortality. For stroke, supplemental oxygen probably does not reduce disability. In patients with acute myocardial infarction, supplemental oxygen probably does not reduce chest pain, recurrent myocardial infarction, or the need for a coronary revascularisation intervention.

Understanding the recommendations

The infographic summarises the benefits and harms of oxygen therapy.

Scope of recommendations

Our recommendations apply to critically ill or surgical patients with sepsis. They also apply to patients who are en route to hospital in an ambulance and to those who are hospitalised.

We did not consider patients with uncomplicated surgery. There is a separate body of evidence, mostly in the elective surgical setting.¹⁸ There is an unresolved debate about whether supplemental oxygen reduces the risk of






PRACTICAL ISSUES	
Oxygen therapy	
 RECOVERY & ADAPTATION	An attached oxygen delivery device may hinder a patient's freedom of movement, potentially being a barrier to interaction with care givers and healthcare providers, and increasing the risk of delirium and falls
 COORDINATION OF CARE	The oxygen delivery device must routinely be monitored to ensure it is in the right position and tolerated well by the patient
 ADVERSE EFFECTS, INTERACTIONS & ANTIDOTE	The delivery of supplemental oxygen can be irritating and lead to adverse outcomes such as epistaxis (nasal cannulae), claustrophobia (face mask), pharyngitis, odynophagia, and tracheal stenosis (endotracheal tube)
 EMOTIONAL WELL-BEING	Oxygen therapy might provide comfort for some people or their families
 COSTS & ACCESS	Routinely providing supplemental oxygen to non-hypoxaemic patients would lead to a routine cost of supplying oxygen gas, humidification, and delivery devices (nasal cannulae, face masks, endotracheal tubes)

Fig 3 | Practical issues about use of oxygen therapy for patients

surgical site infections. Our recommendations may not apply to young children (particularly neonates). There is a separate body of evidence and considerations such as necrotising enterocolitis and retinopathy of prematurity.¹⁹

Upper limit of oxygen therapy

- The panel makes a strong recommendation that, if supplemental oxygen is administered, clinicians ensure a maximum SpO₂ of 96%
 - This is because saturation above this level likely causes a small but important increased risk of death without plausible benefit. It is probable that the optimal upper SpO₂ limit is lower than 96%, but exactly how much lower is unknown. Patients randomised to more liberal oxygen therapy typically achieved a SpO₂ >96%. The data from the trials provide only limited support for any particular upper threshold, including the 96% chosen by the panel.

Lower limit of oxygen therapy

- For patients with myocardial infarction or stroke, the panel makes a strong recommendation against initiating supplemental oxygen when the initial SpO₂ is >92%

- In patients with myocardial infarction or stroke, there are probably no benefits to initiating oxygen therapy when SpO₂ is >92%, and it may cause harm.

- The panel makes a weak recommendation against initiating oxygen in these patients with a SpO₂ of 90-92%
 - There may not be any benefits for patients with this lower SpO₂ (90-92%). Fewer patients with this SpO₂ range at baseline were included in the trials, so the panel had less certainty in the results. There is no evidence of benefit from supplemental oxygen initiated in patients with myocardial infarction and stroke whose SpO₂ is ≥90%, but there exists at least a modest risk of harm.

The panel did not issue recommendations for all patients or for other conditions because there were too few participants in the clinical trials who had a baseline SpO₂ <95%.

Values and preferences

The panel believes that almost all patients would value avoiding even a small increased risk of death with supplemental oxygen. Although the panel viewed nasal and throat irritation and a decrease in mobility from oxygen

Box 2 | Examples of conditions that might benefit from higher or lower oxygen saturation thresholds

Lower target (such as SpO₂ 88-92%)

- Patients at risk of hypercapnic respiratory failure, for example:
 - Chronic obstructive pulmonary disease
 - Obesity hypoventilation
 - Neuromuscular respiratory diseases
 - Obstructive sleep apnoea
 - Decreased central respiratory drive (such as sedative overdose, stroke, encephalitis)

Higher target (such as SpO₂ approaching 100%)

- Carbon monoxide poisoning
- Cluster headaches
- Sickle cell crisis
- Pneumothorax

Table 2 | New evidence which has emerged after initial publication

Date	New evidence	Citation	Findings	Implications for recommendation(s)
There are currently no updates to the article.				

therapy as unimportant, they felt that most patients would not choose to endure even a minor inconvenience if there is probably no benefit.

Practical considerations

Figure 3 outlines the key practical issues about the use of oxygen therapy for patients.

A target SpO₂ range of 90-94% seems wide enough to allow for normal fluctuation, and is likely low enough to avoid harm.

Upper thresholds for SpO₂ in patients at risk of hypercapnic respiratory failure should be lower than for other patients (see box 2 for some common examples). Excessive oxygen could increase the risk of needing mechanical ventilation in these patients. Other existing evidence supports a target SpO₂ of about 88-92% in such patients.²⁰ Box 2 also shows a small number of acute illnesses with specific evidence to support more oxygen.

Shared decision making

The patient panellists said that oxygen therapy is often given to patients with insufficient discussion and explanation. Clearer information may reduce anxiety and improve patient satisfaction in patients where oxygen is needed.

Costs and resources

Patients are unlikely to view the modest cost of oxygen as excessive, particularly in settings where they do not directly pay for their care.

A target SpO₂ range (rather than a lower limit without an upper limit) will need closer monitoring by the healthcare team. Our recommendations do not consider healthcare payer considerations. We suggest a target SpO₂ range that is sufficiently wide that it does not require excessive attention (such as 90-94%). Some patients will have wider SpO₂ fluctuations and may therefore require a wider target range; these patients may also benefit from closer monitoring.

HOW PATIENTS WERE INVOLVED IN THE CREATION OF THIS ARTICLE



Three people with lived experience of acute medical conditions requiring hospitalisation were members of the panel. They identified and rated outcomes, and helped lead the discussion on values and preferences in a videoconference and email discussions before the full panel meetings. They noted that patients are often underinformed about the reason for and implications of supplemental oxygen therapy.

EDUCATION IN PRACTICE

- How do you use supplemental oxygen in medical patients?
- Based on this article, how do you think your practice might change? Is there anything that you would say to your patient or do differently?
- How might you share this information with your organisation or review local policies on oxygen targets?

Future research

There were no robust data comparing supplemental oxygen to no oxygen in patients with a SpO₂ <90%, so the impact of oxygen therapy in such patients is uncertain.

Addressing the following gaps in our knowledge may inform decision makers and future guideline recommendations:

- Does supplemental oxygen provide benefit to patients experiencing a stroke or myocardial infarction with a SpO₂ <92% (such as 85-92%)?
- Is supplemental oxygen harmful in patients with medical conditions other than stroke or myocardial infarction with a SpO₂ 85-94%?

Possible mechanisms

The reasons why excessive supplemental oxygen increases mortality are uncertain. Excessive oxygen can lead to reduced cardiac output, vasoconstriction, inflammation, and oxidative stress.²¹ In addition, excessive oxygen might lead to falsely reassuring SpO₂ values and make it difficult to recognise when a patient's condition worsens.

Updates to this article

Table 2 shows evidence that has emerged since the publication of this article. As new evidence is published, a group will assess the new evidence and make a judgment on to what extent it is expected to alter the recommendation.

Contributors: All panel members participated in the teleconferences or email discussions and met all authorship criteria.

Competing interests: All authors have completed the *BMJ* Rapid Recommendations interests disclosure form, and a detailed description of all disclosures is reported in appendix 2 on [bmj.com](http://www.bmj.com). As with all *BMJ* Rapid Recommendations, the executive team and *The BMJ* judged that no panel member had any financial conflict of interest. Professional and academic interests are minimised as much as possible, while maintaining necessary expertise on the panel to make fully informed decisions. DK Chu, LH-Y Kim, and W Alhazzani co-authored the systematic review that formed the evidence base for this guideline. RAC Siemieniuk, T Agoritsas, PO Vandvik, L Lytvyn, and GH Guyatt are members of the GRADE Working Group: *BMJ* Rapid Recommendations adheres to GRADE methods.

Funding: This guideline was not funded.

Transparency: RAC Siemieniuk affirms that the manuscript is an honest, accurate, and transparent account of the recommendation being reported; that no important aspects of the recommendation have been omitted; and that any discrepancies from the recommendation as planned (and, if relevant, registered) have been explained.

Provenance and peer review: Commissioned; externally peer reviewed

- 1 Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. *Lancet* 2018;391:1693-705. 10.1016/S0140-6736(18)30479-3 pmid:29726345.
- 2 Siemieniuk RA, Agoritsas T, Macdonald H, Guyatt GH, Brandt L, Vandvik PO. Introduction to BMJ Rapid Recommendations. *BMJ* 2016;354:i5191. 10.1136/bmj.i5191 pmid:27680768.
- 3 Guyatt GH, Oxman AD, Vist GE, et al. GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008;336:924-6. 10.1136/bmj.39489.470347.AD pmid:18436948.
- 4 Hale KE, Gavin C, O'Driscoll BR. Audit of oxygen use in emergency ambulances and in a hospital emergency department. *Emerg Med J* 2008;25:773-6. 10.1136/emj.2008.059287 pmid:18955625.
- 5 Burls A, Emparanza JI, Quinn T, Cabello JB. Oxygen use in acute myocardial infarction: an online survey of health professionals' practice and beliefs. *Emerg Med J* 2010;27:283-6. 10.1136/emj.2009.077370 pmid:20385680.
- 6 Blodgett AN. The continuous inhalation of oxygen in cases of pneumonia otherwise fatal, and in other diseases. *Boston Med Surg J* 1890;123:481-410.1056/NEJM189011201232101.
- 7 Report of Societies. Oxygen therapy. *BMJ* 1920;i:150-2.
- 8 Kallstrom TJ. American Association for Respiratory Care (AARC). AARC clinical practice guideline: oxygen therapy for adults in the acute care facility—2002 revision & update. *Respir Care* 2002;47:717-20.pmid:12078655.
- 9 Powers WJ, Rabinstein AA, Ackerson T, et al. American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2018;49:e46-110. 10.1161/STR.000000000000158 pmid:29367334.
- 10 Kobayashi A, Czlonkowska A, Ford GA, et al. European Academy of Neurology and European Stroke Organization consensus statement and practical guidance for pre-hospital management of stroke. *Eur J Neurol* 2018;25:425-33. 10.1111/ene.13539 pmid:29218822.
- 11 O'Gara PT, Kushner FG, Ascheim DD, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2013;127:e362-425.pmid:23247304.
- 12 Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2018;39:119-77. 10.1093/eurheartj/ehx393 pmid:28886621.
- 13 Roffi M, Patrono C, Collet JP, et al. ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2016;37:267-315. 10.1093/eurheartj/ehv320 pmid:26320110.
- 14 O'Driscoll BR, Howard LS, Earis J, Mak V. British Thoracic Society Emergency Oxygen Guideline Group BTS Emergency Oxygen Guideline Development Group. BTS guideline for oxygen use in adults in healthcare and emergency settings. *Thorax* 2017;72(Suppl 1):i1-90. 10.1136/thoraxjnl-2016-209729 pmid:28507176.
- 15 Beasley R, Chien J, Douglas J, et al. Thoracic Society of Australia and New Zealand oxygen guidelines for acute oxygen use in adults: 'Swimming between the flags'. *Respirology* 2015;20:1182-91. 10.1111/resp.12620 pmid:26486092.

- 16 Roffe C, Nevatte T, Sim J, et al. Stroke Oxygen Study Investigators and the Stroke Oxygen Study Collaborative Group. Effect of routine low-dose oxygen supplementation on death and disability in adults with acute stroke: the Stroke Oxygen Study Randomized Clinical Trial. *JAMA* 2017;318:1125-35. 10.1001/jama.2017.11463 pmid:28973619.
- 17 Hofmann R, James SK, Jernberg T, et al. DETO2X-SWEDEHEART Investigators. Oxygen therapy in suspected acute myocardial infarction. *N Engl J Med* 2017;377:1240-9. 10.1056/NEJMoa1706222 pmid:28844200.
- 18 Wetterslev J, Meyhoff CS, Jørgensen LN, Gluud C, Lindschou J, Rasmussen LS. The effects of high perioperative inspiratory oxygen fraction for adult surgical patients. *Cochrane Database Syst Rev* 2015;(6):CD008884.pmid:26110757.
- 19 Askie LM, Darlow BA, Finer N, et al. Neonatal Oxygenation Prospective Meta-analysis (NeOProM) Collaboration. Association between oxygen saturation targeting and death or disability in extremely preterm infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. *JAMA* 2018;319:2190-201. 10.1001/jama.2018.5725 pmid:29872859.
- 20 Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. *BMJ* 2010;341:c5462. 10.1136/bmj.c5462 pmid:20959284.
- 21 Hafner S, Beloncle F, Koch A, Radermacher P, Asfar P. Hyperoxia in intensive care, emergency, and peri-operative medicine: Dr. Jekyll or Mr. Hyde? A 2015 update. *Ann Intensive Care* 2015;5:42. 10.1186/s13613-015-0084-6 pmid:26585328.
- 22 Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength. *J Clin Epidemiol* 2013;66:726-35. 10.1016/j.jclinepi.2013.02.003 pmid:23570745.
- 23 Guyatt GH, Oxman AD, Kunz R, et al. GRADE Working Group. Going from evidence to recommendations. *BMJ* 2008;336:1049-51. 10.1136/bmj.39493.646875.AE pmid:18467413.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to <http://group.bmj.com/group/rights-licensing/permissions>

¹Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton L8S 4K1, Canada

²Department of Medicine, McMaster University, Hamilton L8S 4K1, Canada

³Departament de Pneumologia, Hospital de la Santa Creu i Sant Pau. Barcelona, Catalonia 08041, Spain

⁴Division of Pulmonary Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland

⁵Faculty of Medicine, Geneva University, 1206 Geneva, Switzerland

⁶Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada

⁷Division General Internal Medicine, University Hospitals of Geneva, 1205 Geneva, Switzerland

⁸Alberta Health Services, Calgary, Alberta T1Y 6J4, Canada

⁹Divisions of Pulmonology and Medical Intensive Care, Stellenbosch University, Cape Town 7505, South Africa

¹⁰Departments of Internal Medicine and Biochemistry & Molecular Genetics, American University of Beirut Faculty of Medicine and Medical Center, Beirut 1107 2020, Lebanon

¹¹Salt Lake City, Utah 84106, USA

¹²Ottawa, Ontario K2P 1C8, Canada

¹³Hatley, Quebec J0B 4B0, Canada

¹⁴Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway

¹⁵Division Clinical Epidemiology, University Hospitals of Geneva, 1205 Geneva, 1205, Switzerland